Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Is ondansetron cost effective?

J Bonneterre1

  • 1Centre Oscar Lambret, Lille, France.

Pharmacoeconomics
|November 4, 1994
PubMed
Summary
This summary is machine-generated.

The study found that ondansetron, a 5-Hydroxytryptamine3 (5-HT3) receptor antagonist, significantly reduced hospital stays for chemotherapy patients. This suggests ondansetron may offer economic benefits despite its higher acquisition cost.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-time reverse-transcription PCR to quantify a panel of 19 genes in breast cancer: relationships with sentinel lymph node invasion.

The International journal of biological markers·2017
Same author

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Analysis of Arrestin Recruitment to Chemokine Receptors by Bioluminescence Resonance Energy Transfer.

Methods in enzymology·2016
Same author

[Systemic treatment of brain metastases from breast cancer].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2015
Same author

A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

[What do clinicians do with the results of the systematic staging imaging at the time of the breast cancer diagnosis?].

Gynecologie, obstetrique & fertilite·2014
Same journal

Balancing Access and Value in Multi-Indication Medicines: Implications of PD-L1 Broad Listings in Australia.

PharmacoEconomics·2026
Same journal

Applications of Structural Expert Elicitations for Economic Evaluations: A Systematic Review Update.

PharmacoEconomics·2026
Same journal

Community Pharmacist Preferences for Providing a Dose Administration Aid Service in Australia: A Discrete Choice Experiment.

PharmacoEconomics·2026
Same journal

A Critical Systematic Review of Modelling Approaches and Methodologies used in Hyperlipidaemia Economic Evaluations.

PharmacoEconomics·2026
Same journal

Deriving a Korean SF-6Dv2 Value Set Using a Discrete Choice Experiment with Duration.

PharmacoEconomics·2026
Same journal

Correction: Ten Recommendations for Modelling Cost Effectiveness of Screening: Perspectives of an International Stakeholder Group.

PharmacoEconomics·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacoeconomics
  • Clinical Pharmacy

Background:

  • 5-Hydroxytryptamine3 (5-HT3) receptor antagonists represent a significant advancement in managing chemotherapy-induced nausea and vomiting (CINV).
  • These novel antiemetics have a higher acquisition cost compared to traditional antiemetic therapies.
  • Evaluating the economic impact of ondansetron is crucial for healthcare resource allocation.

Purpose of the Study:

  • To assess the economic consequences of administering ondansetron in a hospital setting.
  • To compare hospital stay duration and overall costs between patients receiving ondansetron and standard antiemetic therapy.
  • To determine the direct costs associated with emesis episodes.

Main Methods:

  • A three-part study was conducted, including retrospective and prospective phases.

Related Experiment Videos

  • Retrospective analysis compared hospital stay lengths and costs for patients with varying ondansetron exposure.
  • Prospective analysis quantified the costs of emesis, including nursing time and ancillary services.

    • Main Results:

    • Patients who consistently received ondansetron had a significantly shorter average hospital stay compared to those who never received it.
    • The study identified multiple cost components associated with vomiting, such as nursing time and laundry expenses.
    • Quality of life data was difficult to interpret due to low patient completion rates.

    Conclusions:

    • Ondansetron administration may lead to reduced hospital lengths of stay, potentially offsetting its higher initial cost.
    • Further research is needed to fully elucidate the economic benefits and quality of life improvements associated with ondansetron therapy.
    • Pharmacoeconomic evaluations are essential for optimizing antiemetic strategies in cancer care.